Rebecca Martisek
Family · Dallas, TXNPI 1164181574
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,818 and has fallen 99.2% since, to $15 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$483
- Boston Scientific$407
- Amneal Pharmaceuticals LLC$329
- Acadia Pharmaceuticals Inc$229
- UCB, Inc.$219
- Teva Pharmaceuticals USA, Inc.$174
- plus $2K from 36 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$3,62199%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,647 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 212 | $213,890 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 245 | $7,588 |
| Rasagiline Mesylate | 18 | $2,744 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 36 | $1,672 |
| Gabapentin | 97 | $1,455 |
| Donepezil Hcl | 114 | $1,432 |
| AmantadineAmantadine Hcl | 18 | $1,300 |
| Primidone | 42 | $1,164 |
| Memantine Hcl | 33 | $625 |
| RivastigmineRivastigmine Tartrate | 17 | $568 |
| Topiramate | 34 | $493 |
| Propranolol Hcl ErPropranolol Hcl | 16 | $422 |
| Propranolol Hcl | 23 | $384 |
| Quetiapine Fumarate | 39 | $361 |
| Baclofen | 11 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $329 | $213,890212 claims |
| Upsher-smith Laboratories LLCTopiramate | $34 | $49334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Dallas
- David WeirDallas$959K
- Sie ThomasDallas$197K
- Marcia HarrisDallas$156K
- Miles HortonDallas$72K
- Natasha SimmonsDallas$38K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.